• Profound Medical entered a co-education agreement with Telix Pharmaceuticals to promote PSMA-PET imaging alongside the TULSA-PRO prostate therapy platform.
• Program targets urologists, radiologists, nuclear medicine physicians, and prostate cancer centers to drive PSMA-informed patient selection and treatment planning.
• Collaboration aims to expand TULSA-PRO adoption by using PSMA-PET to screen out metastatic disease and refine eligibility for higher-risk patients.
• Profound is developing PSMA-PET/MR image-fusion for a future Treatment Delivery Console software release to integrate PSMA-PET data into TULSA planning.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Profound Medical Corp. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610090745PRIMZONEFULLFEED9842859) on October 09, 2026, and is solely responsible for the information contained therein.